Search Results
Search Results For
Study rationale One in every three U.S. adults, about 78 million Americans, have high blood pressure, the single most important and most common risk factor for cardiovascular disease Only 51% of Americans treated for hypertension are adherent to long-term medication therapy Only 52% have their blood pressure under control The total health and economic costs…
Read More
We’ll be talking omni-channel scaling, behavioral data insights and our compliant comprehensive solutions for pharma brands that can launch in 90 days. See more about what we’ll be talking about and schedule time to chat here.
Read More
Medisafe is pleased to share the latest results from a University of Sydney study, showing that mobile apps can have a significant impact on those living with coronary heart disease. Following an initial study conducted in 2016 to identify the leading medication management platform, in which Medisafe was found to be the top performing solution,…
Read More
The FDA’s Groundbreaking Digital Guidelines for Software-Enhanced Medications Coming in this Year A pivotal moment in the convergence of healthcare and technology Software-Enhanced Medications: FDA’s New Draft Guidelines and the Role of Digital Platforms in Prescription Drug Use PDURS: LEARN MORE PDURS: What Experts are Saying PDURS: How Patients Benefit See the six ways that…
Read More
Lorna Weir from Elevate Healthcare Marketing, Stacey Meltzer Wasserman from Medisafe®, as well as KJT’s Katy Palmer, PhD and Ellen Gordon discuss bridging the worlds between insights, advertising, digital solutions, advocacy, and more.Among the covered topics: – The importance of representing and elevating the patient voice – Solutions to overcome the unique hurdles of the…
Read More
MIAMI — June 7, 2018 — Medisafe, the leading medication management platform with almost four and a half million registered users, today released data showing that previously non-adherent HIV patients increase their prescription refills after they start using the company’s mobile app. These results are part of a landmark study conducted by IQVIA, a leading global provider…
Read More
Want to keep current on the FDA’s Draft Guidelines for Prescription Drug Use Related Software (PDURS)? Follow the LinkedIn profiles of these professionals at the forefront of integrating digital health solutions with pharmaceutical products affected by PDURS. PDURS: The Agency Perspective Martin Culjat, PhD, Eversana – Martin Culjat is the Senior Vice President and Global…
Read More
The FDA’s draft guidelines for Prescription Drug Use Related Software (PDURS) have drawn significant attention from the legal community. Law firms and legal experts have provided detailed analyses and comments, focusing on the potential implications for pharmaceutical companies and digital health innovators. Here is a summary of five notable responses from law firms or lawyers…
Read More
The FDA’s Draft Guidelines for Prescription Drug Use Related Software (PDURS) have sparked considerable discussion among various stakeholders, including pharmaceutical companies, healthcare organizations, and digital health advocates. While praising and supporting the FDA’s work to issue clear guidance, most also had specific requests for additional clarity, especially about clinical trial requirements for digital health software…
Read More